IGSF1: a biomarker for predicting prognosis, immunotherapy response, and drug candidates in COVID-19 combined hepatocellular carcinoma

Abstract Supplementary Information: The online version contains supplementary material available at 10.1007/s12672-024-01483-2. Article type: Research Article Keywords: Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Hepatocellular carcinoma (HCC), Novel targets, Tumor immune microenvironment, IGSF1, Pan-tissue analysis Authors: Yuanhui Guo, Baixuan Shen, Chaoxuan Lou, Li Wang, Ying Li Affiliations: grid.453074.10000 0000 9797 0900Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology,